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Abstract
Background: Several different classes of medications have been shown to be efficacious at preventing fractures in patients with
osteoporosis. No study has compared real world efficacy at preventing fractures between all currently approved medications.
Objectives: To directly compare the efficacy of all currently available osteoporosis medications by using a large population claims
database.
Methods: The Truven Health Analytics MarketScan® database from 2008 - 2012 was used to identify all patients who started a new
osteoporosis medication. Patients who experienced a fracture after at least 12 months of treatment were identified and risk factors
for fracture for all patients were recorded. Logistic regression was used to account for and quantify the contribution of risk factors,
and to make direct comparisons between different osteoporosis medications.
Results: A total of 51649 patients were included in the cohort, with an average age of 56 years. The overall incidence rate of fracture was 1.55 per 100 person - years of treatment. Orally administered medications had the lowest fracture rates, led by raloxifene
and alendronate (1.24 and 1.54 respectively), while parenterally administered medications including teriparatide and zolerdonic
acid had the highest rates (3.90 and 1.98 respectively). No statistically significant differences found between oral or parenterally
administered bisphosphonate medications.
Conclusions: While patients taking orally administered drugs including bisphosphonates had less frequent incident fracture no
statistically significant differences were found between most drugs in head - to - head comparisons, even considering the route of
administration of bisphosphonates. These findings support previous evidence that minimal differences in efficacy exist between
different osteoporosis medications. This is the first study using a large database to compare all currently available osteoporosis
treatments and will hopefully be augmented by further study to provide more evidence to make clinical decisions on osteoporosis
medication use.
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1. Background
The consequences and complications of osteoporosis
impose a significant amount of morbidity, mortality and
economic burden on patients and societies worldwide. In
the United States, approximately one in five men and one
in two women over the age of 50 will have an osteoporosis
- related fracture (1), resulting in over two million fractures
and $19 billion in related costs each year (2).
Pharmacologic treatments for osteoporosis have been
shown in randomized controlled trials to reduce the incidence of vertebrae fractures by approximately 50% and

non - vertebral fractures by about 30% (3-5). However, despite good compliance the observed incidence of treatment failure or inadequate clinical response has been reported to be considerably higher than in randomized clinical trials. Between 2-26% of compliant patients sustain
a fracture each year while being treated with osteoporosis medications (6-8), and increased rates are found in patients who are less compliant (9-13).
Given that there is a relative paucity of evidence that
directly compares the effectiveness of different osteoporosis medications, clinical decisions on choosing pharmacotherapy for patients often have an element of trial and
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error. Drugs are frequently selected based on reasons other
than efficacy, such as cost, insurance coverage, side effects,
route of administration and interactions with other drugs
or medical conditions. Studies that compare the efficacy
of osteoporosis drugs would be useful to lend a quantitative, evidence - based element to making these decisions.
This study retrospectively used the MarketScan database to
quantify and compare real - world fracture rates among patients on each osteoporosis medication. We hypothesized
that patients on medications that are more frequently administered orally would have the highest rate of fractures,
followed by self - injectable medications, and then intravenous, intramuscular and medications administered in
the hospital and office.
2. Methods
2.1. Data Source
The Truven Health Analytics MarketScan® Commercial
Claims and Encounters database from 2008 - 2012 was used
to identify patients for the study. The database contains
de - identified demographic information and paid claims
for inpatient and outpatient medical services and prescriptions for commercial populations.
2.2. Patient Criteria
All patients who started a newly prescribed osteoporosis medication were identified. The medications included in the study were alendronate, calcitonin, denosumab, ibandronate, raloxifene, risedronate, teriparatide
and zolendronic acid. Only patients who had a 12 - month
period with no filled prescriptions for an osteoporosis
medication leading up to starting the new medication
were included in the study. Patients who sustained a fracture within the first 12 months of starting a new osteoporosis medication were excluded from the study to allow time
for therapeutic levels and results to be obtained.
2.3. Outcomes
This cohort was then divided into subgroups by each
medication, and the number of patients who sustained a
fracture at least 12 months after starting a new osteoporosis medication was recorded, as well as demographic information. Primary endpoint of fracture was used as this was
deemed as treatment failure in our intention to treat analysis. Further discussion of our choice of treatment failure
can be found in later sections of this report. Although person years of treatment was used to quantify rate of fracture, we counted each of these as a single incidence of
treatment failure, and did not include a time to event analysis.
2

Type and location of fracture were also identified by
ICD - 9 diagnosis code. In addition, information about risk
factors were collected for each group, including smoking,
alcohol use, rheumatoid arthritis, celiac disease, inflammatory bowel disease, type 1 diabetes, asthma, chronic obstructive pulmonary disease (COPD), osteoarthritis, use of
an oral glucocorticoid medication or a fall in the past 12
months. These factors were all identified in the database
by diagnosis using ICD-9 codes.

2.4. Statistical Analysis
Absolute numbers and proportion of individual sub
- cohorts, as well as unadjusted rates of fracture were
recorded and calculated. Logistic regression was also done
adjusting for all risk factors. Additionally, the logistic regression models were repeated to compare all drugs head
to head with alendronate, which was the most widely prescribed.

3. Results
3.1. Cohort Demographics and Outcomes
A total of 51649 patients met criteria to be included in
the cohort. The average age of these patients was 56.0 years
with a range from 50 - 63, and the majority was female,
with only 3208 males included in the cohort. The average
follow up for fracture surveillance was 732 days, approximately 2 years. This means that on average patients were
followed for 4 years: one year with no osteoporosis drug
use, one year taking a new drug to allow for efficacy to be
built up, and two years of fracture surveillance. There were
1610 patients who experienced a fracture, which amounted
to 3.1% of patients, and a rate of 1.55 fractures per 100 person years of treatment. The distribution of patients by each
drug is listed in Table 1, along with the composition by
drug group of risk factors for fracture. Absolute fracture
rates for patients by each drug are listed in Table 2, and
by type of fracture in Table 3. Absolute fracture rates were
lowest for raloxifene and alendronate, and higher for less
commonly used, parenterally administered drugs including zoledronic acid and teriparatide. The majority of fractures by location that were capture by ICD - 9 codes were
wrist fractures, although almost half of the fractures were
not coded as a hip, wrist or vertebral fracture.
Patients taking denosumab were originally included
in the study but only 9 such patients met inclusion criteria. Given the relatively small number, they were excluded
from the analysis.
Int J Endocrinol Metab. 2018; 16(3):e12104.
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Table 1. Demographic Information and Risk Factors for Patients Taking each Osteoporosis Medicationa
Medication

Alendronate

Calcitonin

Ibandronate

Raloxifene

Risedronate

Teriparatide

Zoledronic Acid

Total

26395

1074

9956

4753

8815

524

132

51649

2035 (7.7)

139 (13.0)

336 (3.4)

8 (0.17)

501 (5.7)

74 (14.1)

12 (9.1)

3208 (6.2)

Total number of
patients
Male patients

56.8

57.1

56.6

56.7

56.5

56.9

56.9

56.0

Smoking

1759 (6.7)

78 (7.3)

585 (5.9)

187 (3.9)

466 (5.3)

46 (8.8)

6 (4.6)

5543 (10.7)

Alcohol abuse

177 (0.67)

8 (0.74)

63 (0.62)

17 (0.36)

35 (0.40)

6 (1.15)

1 (0.76)

580 (1.1)

Average age

Rheumatoid arthritis

1287 (4.9)

77 (7.2)

435 (4.4)

159 (3.4)

468 (5.3)

44 (8.4)

12 (9.1)

3947 (7.6)

Celiac disease

183 (0.69)

14 (1.3)

54 (0.54)

23 (0.48)

64 (0.73)

5 (0.95)

1 (0.76)

132 (0.3)

Inflammatory bowel
disease

1562 (5.9)

96 (8.9)

626 (6.3)

282 (5.9)

577 (6.6)

41 (7.8)

11 (8.3)

6393 (12.4)

Type I diabetes

625 (2.4)

34 (3.2)

181 (1.8)

77 (1.6)

200 (2.27)

10 (1.9)

5 (3.8)

2086 (4.0)

Type II Diabetes

8657 (32.8)

347 (32.3)

2768 (27.6)

1359 (28.6)

2777 (31.5)

162 (30.9)

44 (33.2)

16114 (31.2)

Use of oral
glucocorticoid drug

14867 (56.3)

709 (66.0)

5947 (59.7)

2660 (56.0)

5174 (58.7)

325 (62.0)

90 (68.2)

29772 (57.6)

Asthma, COPD, chronic
bronchitis, emphysema

5433 (20.6)

309 (28.8)

2028 (20.4)

891 (18.8)

1808 (20.5)

151 (28.8)

35 (26.5)

10655 (20.6)

427 (1.6)

21 (2.0)

159 (1.6)

49 (1.0)

118 (1.3)

14 (2.7)

2 (1.5)

790 (1.5)

7092 (26.9)

362 (33.7)

2796 (28.1)

1269 (26.7)

2329 (26.4)

198 (37.8)

47 (35.6)

14093 (27.3)

Fall in past 12 months
Osteoarthritis or
degenerative joint
disease
a

All values listed are number of patients with percent in brackets, except for age, which is expressed in years.

Table 2. Fracture Rate and Follow - up Period for Patients by each Osteoporosis Medicationa
Medication

Alendronate

Calcitonin

Ibandronate

Raloxifene

Risedronate

Teriparatide

Zoledronic Acid

Total

26395

1074

9956

4753

8815

524

132

51649

Total number of patients
Fractures

804

37

325

119

280

40

5

1610

Patients with fracture(s) (%)

3.05

3.45

3.26

2.50

3.18

7.63

3.79

3.12

Average follow-up (days)

724

717

741

735

751

714

697

732

Fracture rate per 100 person
years

1.54

1.75

1.61

1.24

1.54

3.9

1.98

1.55

a

No statistically significant differences were found in fracture rates aside from the rate for teriparatide being higher than all other ones. A more detailed and controlled
head - to - head analysis can be seen in Table 5.

Table 3. Number of Fractures in Different Sites by each Osteoporosis Medication
Medication
Total number of patients

Alendronate

Calcitonin

Ibandronate

Raloxifene

Risedronate

Teriparatide

Zoledronic Acid

Total

26395

1074

9956

4753

8815

524

132

51649

Hip fractures

87

5

31

13

26

6

0

168

Wrist fractures

273

4

103

34

99

3

2

518

Vertebrae fractures

89

8

45

19

34

2

0

197

Other fractures

355

20

146

53

121

29

3

727

Total Fractures

804

37

325

119

280

40

5

1,610

3.2. Logistic Regression Analysis
Logistic regression analysis yielded a controlled contribution towards fractures for different risk factors to fracInt J Endocrinol Metab. 2018; 16(3):e12104.

tures, as seen in Table 4. Most risk factors had statistically significant odds ratios greater than 1, indicating an
increased risk of fracture. Experiencing a fall in the 12
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months prior to starting an osteoporosis medication was
by far the most significant risk factor for experiencing a
fracture while being treated for osteoporosis in our cohort.
In descending order of magnitude of risk, having a prior
fall was followed by carrying a diagnosis of diabetes, osteoarthritis, alcohol abuse, and being a smoker. Other risk
factors that appeared to contribute to fractures included
inflammatory bowel disease, use of an oral glucocorticoid,
asthma and COPD. Factors found not to have a statistically
significant correlation included rheumatoid arthritis and
celiac disease. Table 5 shows the results of the logistic regressions directly comparing each drug to alendronate.
For this analysis, confounders that were adjusted for were
smoking, alcohol abuse, rheumatoid arthritis, inflammatory bowel disease, celiac disease, type 1 diabetes, type 2 diabetes, use of oral glucocorticoid, asthmas, COPD, chronic
bronchitis, emphysema, fall in past 12 months, osteoarthritis and degenerative joint disease. Except for raloxifene,
the odds ratios were above 1, indicating increased risk of
fracture relative to alendronate, but only teriparatide was
statistically significant (OR 2.347, 95% CI 1.676 - 3.286). Although the odds ratio for raloxifene was less than 1, indicating decreased risk of fracture, it was not statistically significant.
4. Discussion
The results of the direct comparison of different osteoporosis medications were opposite of our hypothesis. No
statistically significant results were found based on route
of administration of bisphosphonates, nor between raloxifene and alendronate. Previous randomized trials and retrospective studies have found no difference between alendronate and raloxifene, and other reviews and analyses
have concluded that minimal differences in efficacy exist
between different medication options (4, 14-16). The fact
that our study did not find statistically significant differences supports the results from these studies.
The only statistically significant difference in fracture
rate found by the study was between teriparatide and alendronate. This likely represents confounding by indication,
since many patients taking teriparatide are prescribed it
due to an indication of previous fractures, or especially low
bone mineral density.
For almost all risk factors that were captured by available data, analysis showed statistically significant results
for them increasing the likelihood of experiencing a fracture. The risk factors that were chosen in the study were
identified to mirror the validated FRAX model risk factors,
as much as was possible by using ICD - 9 codes. This analysis
showed experiencing a recent fall to be by far the most significant risk factor. It is worth keeping in mind that most
4

studies evaluating risk factors looked at general populations, whereas our cohort included only patients currently
being treated for osteoporosis. Similar results have also
been found by studies that have identified risk factors for
treatment failure while on an osteoporosis medication (17,
18). Given the significant magnitude of risk found in this
study and other for patients who have had a recent fall or
fracture, it may be worth considering more intensive therapy for these patients, including possibly using multiple
agents when initiating therapy.
The overall fracture rate for all patients included in the
study of 1.55 fractures per 100 person years of treatment
was at the lower end of the spectrum from previous studies. Although no studies have looked at such a wide range
of medications in a single study, rates of fractures per 100
person years have been reported between 0.8 and 9.5, with
most between 1 and 4 (6-8, 12, 15, 17, 19-26). These rates, as
well as data from randomized controlled trials have found
relative risk reduction of approximately 0.60 compared to
patients not taking osteoporosis medications (16). The results in our study therefore lie somewhere in between the
greater efficacy found in trials and the lesser efficacy that
has been noted in “real world” retrospective studies. A control group cohort was initially included in this study but removed in favor of directly comparing medications to each
other.
Ultimately it is a difficult comparison to make between
this study and others since there are many parameters
that vary between them, including assessments of compliance, duration of follow up and the medications that
were studies. In the present study, no assessment of compliance was made, but inclusion criteria required a one year “wash out” period and a one - year period for efficacy
to be achieved. It is possible that we included patients who
had been on past long term (i.e. 5 or more years of oral bisphosphonates or 3 or more years of I.V. bisphosphonates),
and despite a “wash out” period of one year, that they were
still exhibiting an effect of the bisphosphonate given the
known long half - life of these drugs in bone. If they were
restarted on a bisphosphonate after a “drug holiday” it may
have accounted for the lower fracture rate in this group,
but there’s no way in knowing that from this database analysis.
Although many other studies have reported treatment
failure as 2 or more fractures, and most efficacy studies
control for patient compliance, we specifically did not
want to use these methods (6, 26). We felt that without
controlling for compliance we would capture a true, intention - to - treat efficacy for each drug, and have compliance
(or non - compliance) contribute to their overall efficacy
versus other medications. We also reported rates of a single fracture since we felt that there is a more significant
Int J Endocrinol Metab. 2018; 16(3):e12104.
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Table 4. Logistic Regression Results Indicating Risk Associated with Fracture While Being Treated for Osteoporosis, for each Factor
Fracture Risk Factor

Wald Chi - Square

P value

Odds Ratio

95% Confidence Limits

Smoking

17.97

< 0.0001

1.457

1.224

1.733

Alcohol abuse

5.19

0.023

1.665

1.074

2.582

Rheumatoid arthritis

0.21

0.65

1.049

0.852

1.292

Celiac disease

0.51

0.48

1.227

0.700

2.148

Inflammatory bowel disease

4.35

0.037

1.215

1.012

1.460

Type I diabetes

19.89

< 0.0001

1.786

1.384

2.305

6.31

0.012

1.149

1.031

1.280

Use of oral glucocorticoid drug

24.22

< 0.0001

1.337

1.191

1.501

Fall in past 12 months

438.44

< 0.0001

7.328

6.082

8.830

Osteoarthritis or degenerative joint disease

105.43

< 0.0001

1.731

1.559

1.922

Asthma, COPD, chronic bronchitis, emphysema

Table 5. Logistic Regression Results for Head - to - head Drug Comparisons to Alendronate, with Regards to Fracture Incidencea
Drug

Unadjusted Odds Ratio

95% Confidence Limit

Odds Ratio

95% Confidence Limit

Calcitonin

1.14

0.81

1.59

1.03

0.73

1.44

Ibandronate

1.07

0.94

1.22

1.08

0.94

1.23

Raloxifene

0.82

0.67

0.99

0.87

0.72

1.07

Risendronate

1.04

0.91

1.20

1.07

0.93

1.23

Teriparatide

2.63

1.89

3.66

2.35

1.68

3.29

Zolendronic Acid

1.25

0.51

3.07

1.16

0.47

2.86

a

Variables adjusted for: smoking, alcohol abuse, rheumatoid arthritis, inflammatory bowel disease, celiac disease, type 1 diabetes, type 2 diabetes, use of oral glucocorticoid, asthma, COPD, chronic bronchitis, emphysema, fall in past 12 months, osteoarthritis and degenerative joint disease.

clinical difference between one and zero fractures, than between two and one fractures. For this reason we also gave a
significant amount of time for drug efficacy to be achieved
(12 months), before looking for patients who experienced
a fracture.

medications, this is still an age group where fracture prevention and osteoporosis is a significant health problem,
as evidenced by the over 100000 patients captured in our
study. Finally, having a longer follow up period would also
be useful but was limited by the available data.

The weaknesses of this study include many of the well reported drawbacks of large claims database studies. Most
important among these, is that the data integrity is dependent on the accuracy of the coding within the database and
that the sub - population within the database may or may
not represent the composition of other populations. The
lack of available bone mineral density data for all patients,
as mentioned above, is also a significant drawback of the
data set and study. Another difficulty in our study specifically was that limited use of newer drugs reduced the ability to identify statistically significant differences in comparing different medications. As previously mentioned,
more recently approved drugs account for a small proportion of patients included in the study. The average age is
also a limitation of the study, as the patients captured in
this cohort were relatively young, with an average age of 56
and a range of 50 to 63 years of age. Although this does not
capture the age range of all patients who use osteoporosis

More studies comparing the efficacy of osteoporosis
medication would certainly serve to help direct evidence
- based decision making for health care providers. This
may be more achievable as use of new agents become more
prevalent. Consideration of drug efficacy in specific type of
patients and populations may also identify more specific
indications for individual drugs.

Int J Endocrinol Metab. 2018; 16(3):e12104.

Overall, this study reaffirmed the efficacy of all osteoporosis medications in a large population database study.
Patients taking orally administered drugs including bisphosphonates had less frequent incident fracture, however statistically significant differences were not found in
head - to - head comparisons that accounted for risk factors. Ultimately this supports previous findings that minimal differences in efficacy exist between the different medications, and highlights the paucity of data available for
patients taking more recently approved medications. Previously established risk factors for fracture were also con5

Reynolds AW et al.

firmed to be risk factors for treatment failure across this
large cohort. This is the first study to use a large database
to compare all currently available osteoporosis treatments
and will hopefully be augmented by further study to provide more evidence to make clinical decisions on osteoporosis medication use.
Footnotes
Authors’ Contribution: Study concept and design:
Fox, Kocis; Acquisition of data: Liu; Analysis and interpretation of data: Liu, Reynolds; Drafting of the
manuscript: Reynolds, Skowronski, Liu; Critical revision
of the manuscript for important intellectual content: Fox,
Leslie, Kocis; Statistical analysis: Liu; Administrative, technical and material support: Reynolds; Study supervision:
Fox, Kocis.
Funding/Support: Internal funding for this study was
provided by The Pennsylvania State University, Department of Orthopaedics and Rehabilitation, Orthopaedics
Research Institute Grant.
Role of the Sponsor: The funding organization is a public institutions and had no role in the design and conduct of the study; collection, management, and analysis
of the data; or preparation, review, and approval of the
manuscript.
Statement of Human and Animal Rights: This article
does not contain any studies with human participants or
animals performed by any of the authors.
Statement of Informed Consent: For this type of study
formal consent is not required.
References
1. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S,
et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014;25(10):2359–81. doi: 10.1007/s00198-014-2794-2.
[PubMed: 25182228]. [PubMed Central: PMC4176573].
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A.
Incidence and economic burden of osteoporosis-related fractures in
the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465–75. doi:
10.1359/jbmr.061113. [PubMed: 17144789].
3. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148(3):197–213. [PubMed:
18087050].
4. Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, et
al. Clinical review. Comparative effectiveness of drug treatments to
prevent fragility fractures: a systematic review and network metaanalysis. J Clin Endocrinol Metab. 2012;97(6):1871–80. doi: 10.1210/jc.20113060. [PubMed: 22466336].
5. Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie
F, et al. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord. 2011;12:209. doi: 10.1186/1471-2474-12-209. [PubMed:
21943363]. [PubMed Central: PMC3196921].

6

6. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Silvestri S, et al.
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int. 2008;19(8):1219–23. doi: 10.1007/s00198-0080566-6. [PubMed: 18286217].
7. Prieto-Alhambra D, Pages-Castella A, Wallace G, Javaid MK, Judge
A, Nogues X, et al. Predictors of fracture while on treatment with
oral bisphosphonates: a population-based cohort study. J Bone Miner
Res. 2014;29(1):268–74. doi: 10.1002/jbmr.2011. [PubMed: 23761350].
[PubMed Central: PMC3867340].
8. Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S,
Morelli V, et al. Factors associated with bisphosphonate treatment
failure in postmenopausal women with primary osteoporosis. Osteoporos Int. 2014;25(4):1401–10. doi: 10.1007/s00198-014-2619-3. [PubMed:
24510095].
9. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND:
the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women
treated with oral bisphosphonates. Osteoporos Int. 2012;23(1):223–31.
doi: 10.1007/s00198-011-1535-z. [PubMed: 21308365].
10. Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, et al. Risk
of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int. 2013;24(2):511–21. doi:
10.1007/s00198-012-1984-z. [PubMed: 22588182].
11. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A metaanalysis of osteoporotic fracture risk with medication nonadherence.
Value Health. 2011;14(4):571–81. doi: 10.1016/j.jval.2010.11.010. [PubMed:
21669382].
12. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact
of compliance with osteoporosis therapy on fracture rates in actual
practice. Osteoporos Int. 2004;15(12):1003–8. doi: 10.1007/s00198-0041652-z. [PubMed: 15167989].
13. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E.
The association of adherence to osteoporosis therapies with fracture,
all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17(1):25–39. doi: 10.18553/jmcp.2011.17.1.25.
[PubMed: 21204588].
14. Lin T, Yan SG, Cai XZ, Ying ZM, Yuan FZ, Zuo X. Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of
Seven Head-to-Head Randomized Controlled Trials. Int J Endocrinol.
2014;2014:796510. doi: 10.1155/2014/796510. [PubMed: 24511313].
[PubMed Central: PMC3912893].
15. Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, et al. Fractures
in women treated with raloxifene or alendronate: a retrospective
database analysis. BMC Womens Health. 2013;13:15. doi: 10.1186/14726874-13-15. [PubMed: 23521803]. [PubMed Central: PMC3626542].
16. Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth
MJ, et al. Comparative effectiveness of pharmacologic treatments
to prevent fractures: an updated systematic review. Ann Intern Med.
2014;161(10):711–23. doi: 10.7326/M14-0317. [PubMed: 25199883].
17. Hawley S, Javaid MK, Rubin KH, Judge A, Arden NK, Vestergaard P, et
al. Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study. J Bone Miner Res. 2016;31(1):234–44. doi: 10.1002/jbmr.2595.
[PubMed: 26174968].
18. Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374(3):254–62. doi: 10.1056/NEJMcp1513724.
[PubMed: 26789873].
19. Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR,
Solomon DH. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med. 2008;148(9):637–46.
[PubMed: 18458276]. [PubMed Central: PMC3285566].

Int J Endocrinol Metab. 2018; 16(3):e12104.

Reynolds AW et al.

20. Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int. 2011;22(3):943–54. doi: 10.1007/s00198-010-1309-z. [PubMed:
20532481]. [PubMed Central: PMC3277855].
21. Cadarette SM, Levesque L, Mamdani M, Perreault S, Juurlink DN, Paterson JM, et al. Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults:
a population-based cohort study. CMAJ Open. 2013;1(3):E97–E105.
doi: 10.9778/cmajo.20130036. [PubMed: 25077113]. [PubMed Central:
PMC3986012].
22. Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E. RisedronatE and
ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int. 2009;20(6):973–8.
doi: 10.1007/s00198-008-0772-2. [PubMed: 18946630]. [PubMed Central: PMC2711629].
23. Ferrari S, Nakamura T, Hagino H, Fujiwara S, Lange JL, Watts NB. Longi-

Int J Endocrinol Metab. 2018; 16(3):e12104.

tudinal change in hip fracture incidence after starting risedronate or
raloxifene: an observational study. J Bone Miner Metab. 2011;29(5):561–
70. doi: 10.1007/s00774-010-0249-1. [PubMed: 21225297].
24. LeBlanc ES, Rosales AG, Balasubramanian A, O’Malley CD, Egbuna
O, Friess D, et al. Risk factors for fracture among current, persistent users of bisphosphonates. Osteoporos Int. 2015;26(2):713–25. doi:
10.1007/s00198-014-2941-9. [PubMed: 25354654].
25. Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. Osteoporos Int. 2013;24(8):2345–52. doi: 10.1007/s00198-013-2332-7. [PubMed:
23612793].
26. Diez-Perez A, Adachi JD, Adami S, Anderson FJ, Boonen S, Chapurlat
R, et al. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women
(GLOW). J Bone Miner Res. 2014;29(1):260–7. doi: 10.1002/jbmr.2023.
[PubMed: 23794198]. [PubMed Central: PMC4878143].

7

